Open this publication in new window or tab >>Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]
Introduction: Care transitions, particularly hospital discharge, present significant risks to patient safety. Deficient medication-related discharge communication is a major contributor, posing a substantial risk of harm to older patients. This protocol outlines the Improved Medication Communication and Patient Involvement at Care Transitions (IMPACT-care) intervention study, designed to evaluate the effects of a multi-faceted intervention for older hospitalised patients on medication-related discharge communication compared to usual hospital care.
Methods and analysis: A pre-post intervention study will be conducted in two surgical and one geriatric ward of a university hospital in Sweden. The study will begin with a control period delivering care as usual, followed by a training period and then an intervention period. The intervention comprises four components performed by clinical pharmacists: (1) an information package provided to patients and/or their informal caregivers, (2) preparation of medication-related discharge documentation, (3) facilitation of discharge communication, and (4) a follow-up call to patients or their informal caregiver. Eligible participants are aged ≥ 65 years, manage their own medications independently or with informal caregiver support, and are admitted to the study wards. Both study periods (control and intervention) will last until a total of 115 patients have been included in each period. The primary outcome is the quality of medication-related discharge documentation, assessed using the Complete Medication Documentation at Discharge Measure (CMDD-M). Secondary outcomes include patients' perceptions of involvement in discharge medication communication and their confidence in post-discharge medication management, adherence to medication changes from hospitalisation that persist after discharge, and unplanned healthcare visits following discharge. A process evaluation is planned to explore how the intervention was implemented. Patient inclusion began in September 2024.
Ethics and dissemination: The study protocol has been approved by the Swedish Ethical Review Authority (registration no.: 2023-03518-01 and 2024-04079-02). Results will be published in open-access international peer-reviewed journals, and presented at national and international conferences.
Trial registration number: NCT06610214
National Category
Social and Clinical Pharmacy
Identifiers
urn:nbn:se:uu:diva-552923 (URN)
2025-03-192025-03-192025-03-26